Skip to content
Investment Visual
/
Backtest
Tools
Browse
Stocks
NTRA
Financials
Revenue by product
NTRA
Natera, Inc.
Backtest
NTRA
Overview
Returns
Financials
Holders
Insiders
Summary
Statements
Income
Revenue
Revenue by product
Revenue by region
Gross profit
Operating income
Net income
EPS
EBITDA
Cash flow
Balance sheet
Valuation
Shares and dividends
Costs
Revenue by product
Annual
Quarterly
Revenue by product
Annual
Quarterly
2025, ended Dec 31, 2025
Product revenues
$2.3B
100%
Licensing and other revenues
$10M
<1%
Earlier:
Upfront license and constellation and paternity
to 2017
Other, licensing and other
to 2017
Products by fiscal year
CSV
Products by fiscal year
USD
Line, in USD
2025
2024
2023
2022
2021
2020
2019
2018
2017
Product revenues
2.30B
1.69B
1.07B
0.80B
0.58B
0.38B
0.27B
0.24B
0.20B
Licensing and other revenues
10M
12M
14M
23M
45M
13M
32M
17M
—
Earlier (2)
—
—
—
—
—
—
—
—
5.85M
Upfront license and constellation and paternity
—
—
—
—
—
—
—
—
4.23M
Other, licensing and other
—
—
—
—
—
—
—
—
1.62M
Total
2.31B
1.70B
1.08B
0.82B
0.63B
0.39B
0.30B
0.26B
0.21B
More Natera financials
Revenue
Revenue by region
Gross profit
Operating income
Net income
EPS
Revenue at other companies
BSX
Boston Scientific Corporation
VRTX
Vertex Pharmaceuticals Incorporated
ILMN
Illumina, Inc.
ELV
Elevance Health, Inc.
HUM
Humana Inc.
HCA
HCA Healthcare, Inc.
Tools
Return calculator